

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 591 527 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

02.11.2005 Bulletin 2005/44

(51) Int Cl.7: **C12N 15/13, C07K 16/46,**

C12P 21/08, C12N 5/10,

A61K 39/395

(21) Application number: **04704324.5**

(22) Date of filing: **22.01.2004**

(86) International application number:

PCT/JP2004/000549

(87) International publication number:

WO 2004/072286 (26.08.2004 Gazette 2004/35)

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

AL LT LV MK

(30) Priority: **23.01.2003 JP 2003014793**

(71) Applicants:

- **ONO PHARMACEUTICAL CO., LTD.**
Osaka-shi, Osaka 541-8526 (JP)
- **Honjo, Tasuku**
Kyoto-shi, Kyoto 606-0001 (JP)

(72) Inventors:

- **HONJO, Tasuku**
Kyoto-shi, Kyoto 606-0001 (JP)

- **SHIBAYAMA, Shiro,**
Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)
- **TAKEDA, Kazuhiko,**
Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)
- **MATSUO, Masayoshi,**
Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)
- **YOSHIDA, Takao,**
Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)
- **MIYAMOTO, Masakazu,**
Minase Research Inst. Ono Phar
Mishima-gun, Osaka 618-8585 (JP)

(74) Representative: **Henkel, Feiler & Hänzel**
Möhlstrasse 37
81675 München (DE)

(54) SUBSTANCE SPECIFIC TO HUMAN PD-1

(57) The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a mem-

brane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

EP 1 591 527 A1

Description

Field of the Invention

- 5 [0001] The present invention relates to antibodies specific to human PD-1, bispecific antibodies comprising antibodies against human T cell receptor complex or human B cell receptor complex, polynucleotides encoding them, and the usage of the bispecific antibodies.

Background of the Invention

- 10 [0002] The immune system acquired the mechanism that can respond to various foreign antigens. The mechanism takes the diversity of an antigen receptor by recombination of V, (D) and J fragment in T cells and B cells. Although this mechanism brought about a result that produces autoreactive lymphocytes, these autoreactive lymphocytes are removed by the negative selection in thymus or bone marrow, and are further controlled by the self-tolerance mechanism of clonal deletion or anergy in periphery.

- 15 [0003] Although it is thought that an autoimmune disease is developed by the breakdown of self-tolerance, the researches using various disease murine model have been conducted to elucidate the mechanism of pathogenesis. However, the etiology of an autoimmune disease and the molecular mechanism of self-tolerance remain unclear. In such a situation, existence of the mouse which shows the symptoms of an autoimmune disease caused by a single gene deficient is very important for study the etiology of an autoimmune disease from a molecular biological viewpoint. CTLA4-/-mouse which causes lethal systemic lymphocytes infiltration (Waterhouse P., *et al.*, *Science*, 270:985-988, 1995; Tivol E.A., *et al.*, *Immunity*, 3:541-547, 1995), SHP-1 deficient mothsaten mice (Shultz L.D., *et al.*, *Cell*, 73: 1445-1454, 1993), lyn-/-mouse which shows the symptoms of glomerular nephritis (Hibbs M.L., *et al.*, *Cell*, 83:301-311, 1995), and FCRIIB-/-mouse (Bolland S. & Ravetch J.V., *Immunity*, 13:277-285, 2000) are the representation, and the relations of these molecules and self-tolerance has been studied.

- 20 [0004] The PD-1 gene, which belongs to the immunoglobulin super family, encodes a 55 kDa type I transmembrane protein. Both mouse PD-1 and human PD-1 consist of 288 amino acids, and have signal peptide at N terminal (20 amino acid) and hydrophobic region in the middle part, which is a transmembrane region (*The EMBO J.*, 11(11): 3887-3895, 1992); Japanese patent Publication No. 5-336973; EMBUGenBank/DDJB Acc. No. X67914, *Genomics*, 23:704, 1994; Japanese patent Publication No. 7-291996 (U.S. Patent No. 5629204).

- 30 [0005] In thymus, PD-1 is expressed at the transition phase between CD4-/CD8- to CD4+/CD8+ stage on thymocytes (Nishimura H., *et al.*, *Int. Immunol.*, 8:773-780 (1996), Nishimura H., *et al.*, *J. Exp. Med.*, 191:891-898 (2000)). In periphery, PD-1 is expressed on T cells and B cells activated through the antigen receptor (Agata Y., *et al.*, *Int. Immunol.*, 8:765-772 (1996)), and on activated myeloid lineage cells such as macrophages.

- 35 [0006] PD-1 has ITIM (Immunoreceptor tyrosine-based inhibitory motif) in its intracellular region. Therefore, PD-1 is a negative regulator in immune responses. Since PD-1 deficient mice developed a lupus-like glomerular nephritis and arthritis (C57BL/6 genetic background) (Nishimura H., *et al.*, *Int. Immunol.*, 10:1563-1572, 1998, Nishimura H., *et al.*, *Immunity*, 11:141-151, 1999) and dilated cardiomyopathy-like disease (BALB/c genetic background) (Nishimura H., *et al.*, *Science*, 291:319-322 (2001)), it became clear that PD-1 serves as a regulator for the development of autoimmune disease, especially for the maintenance of self tolerance. Further it has been reported that graft rejection is regulated by inhibition of PD-1 signal (*Journal of Immunology*, 169, 11:6543-6553 (2001)),

Disclosure of the Invention

- 45 [0007] It is thought that PD-1 is a regulator of various autoimmune diseases, and that it is one of causative genes of autoimmune diseases. Control of the PD-1 function can bring about the medical treatment and diagnosis of suppression or enhancement of the immune function, infection, transplant rejection, and neoplasm *etc.* As a result of keen examination, the present inventors reached the present invention concerning the substances that controls the function of PD-1.

- 50 [0008] Stimuli on lymphocytes which control immunity are transmitted mainly through T cell receptor (TCR) in case of T cells, and B cell receptor (BCR) in case of B cells, and then intracellular phosphorylation plays an important role in the molecular mechanism.

- [0009] Since it has been elucidated that PD-1 negatively regulates various immunocompetent cells such as lymphocytes and myeloid cells *etc.* and PD-1 has ITIM (Immunoreceptor tyrosine-based inhibitory motif) in its intracellular region, the present inventors considered that the recruit of de-phosphorylation enzymes (phosphatases) could be involved in the molecular mechanism in the inhibitory signal transduction mediated by PD-1. Therefore, it was hypothesized that making PD-1 colocalize with TCR or BCR can display the PD-1 function.

- [0010] The present inventors confirmed that the inhibitory signal of PD-1 was transmitted with the substance which

physically cross-links PD-1 to TCR or BCR. First, the present inventors confirmed that the above idea was right using anti-PD-1 antibodies and anti-CD3 antibodies. CD3 is a membrane protein expressed on T cells and is one component of TCR complexes. The divalent antibodies were constructed by bridging anti-PD-1 antibodies and anti-CD3 antibodies. The present invention was completed by isolating each cDNA encoding anti-human PD-1 antibody and anti-human TCR antibody and producing bispecific antibody produced by constructing expression vectors that can express fusions proteins comprising each antigen-recognition site of both antibodies.

[0011] The present invention relates to the followings:

- (1) A substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells, and a linker.
- (2) The substance specific to human PD-1 according to (1), wherein the part that recognizes human PD-1 is an antibody against human PD-1 or a partial fragment thereof.
- (3) The substance specific to human PD-1 according to (1), wherein the part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells is an antibody against the membrane protein or a partial fragment thereof.
- (4) The substance specific to human PD-1 according to (1), comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against the membrane protein on cell membrane of human PD-1-expressing cells or a partial fragment thereof, and a linker.
- (5) The substance specific to human PD-1 according to any one of (1), (3) and (4), wherein the membrane protein is human T cell receptor complex or human B cell receptor complex.
- (6) The substance specific to human PD-1 according to (1) or (4), wherein the linker is a peptide.
- (7) A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human T cell receptor complex or a partial fragment thereof, and a linker.
- (8) A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human B cell receptor complex or a partial fragment thereof, and a linker.
- (9) The bispecific antibody according to (7) or (8), wherein the linker is a peptide.
- (10) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
- (11) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:4, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
- (12) A polypeptide complex comprising the polypeptides according to (10) and (11).
- (13) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added.
- (14) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, which is the bispecific antibody according to any one of (7) to (9).
- (15) A polynucleotide encoding the polypeptide according to any one of (10), (11), (13) and (14), a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
- (16) A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9, a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
- (17) A duplication or expression vector comprising the polynucleotide according to (15) or (16).
- (18) A host cell transformed by the duplication or expression vector according to (17).
- (19) A manufacturing method of the substance according to any one of (1) to (6), comprising culturing the host cell according to (18) under conditions to express the substance.
- (20) A manufacturing method of the bispecific antibody according to any one of (7) to (9), comprising culturing the host cell according to (18) under conditions to express the bispecific antibody.
- (21) A manufacturing method of the polypeptide according to any one of (10) to (14), comprising culturing the host cell according to (18) under conditions to express the polypeptide.
- (22) A therapeutic and/or preventive pharmaceutical composition for human PD-1 related-diseases, comprising an effective amount of the substance according to any one of (1) to (6), the bispecific antibody according to any one of (7) to (9), the polypeptide complex according to (12), or the polypeptide according to (13) or (14).

(23) The therapeutic and/or preventive pharmaceutical composition according to (22), wherein the human PD-1 related-diseases are diseases selected from neurodegenerative disease, autoimmune disease, collagenosis, organ transplantation rejection, tumour, and infectious disease.

(24) The therapeutic and/or preventive pharmaceutical composition according to (22), wherein the neurodegenerative diseases are diseases selected from geriopsychosis, Alzheimer disease, Down syndrome, Parkinson's disease, Creutzfeldt-jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt-Jakob disease.

(25) The therapeutic and/or preventive pharmaceutical composition according to (22), wherein the autoimmune diseases are diseases selected from glomerular nephritis, arthritis, dilated cardiomyopathy-like disease, ulcerous colitis, Sjogren syndrome, Crohn disease, systemic erythematodes, chronic rheumatoid arthritis, multiple sclerosis, psoriasis, allergic contact dermatitis, polymyositis, pachyderma, periarteritis nodosa, rheumatic fever, vitiligo vulgaris, insulin dependent diabetes mellitus, Behcet disease, Hashimoto disease, Addison disease, dermatomyositis, myasthenia gravis, Reiter syndrome, Graves' disease, anaemia pernicioosa, Goodpasture syndrome, sterility disease, chronic active hepatitis, pemphigus, autoimmune thrombopenic purpura, and autoimmune hemolytic anemia.

[0012] The part that recognizes human PD-1 in the present invention has only to be a substance that recognizes human PD-1, for example, anti-human PD-1 antibody or a fragment thereof, human PD-1 itself or a fragment thereof, a ligand for human PD-1 or a fragment thereof (Freeman, GJ, *et al.*, *Journal of Experimental Medicine*, 19, 7;1027-1034 (2000)), human PD-L2, and human PD-H3 *etc.*), and a low molecular weight organic compounds *etc.*

[0013] The antibody for human PD-1 or a fragment thereof may be either of complete polyclonal or monoclonal antibody, humanized antibody, complete human antibody, and short antibody thereof (for example, F(ab')₂, Fab', Fab, Fv) *etc.* which contains anti-human PD-1 antibody or a fragment thereof.

[0014] Concretely, they are monoclonal anti-human PD-1 antibodies produced by hybridomas (International Trust Number FERM P-19162) that had been deposited to National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary in Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan at Dec 19, 2002, and had been transferred to International Deposit at June 5, 2003 (International Trust Number FERM BP-8392), which was named J110. Though F(ab')₂, Fab', Fab, and Fv antibody fragments of these antibodies *etc.* are preferable, they don't limit to them.

[0015] F(ab')₂, Fab', Fab, and Fv antibody fragments can be obtained by processing complete antibodies with protease enzyme, and optionally reducing it. They can be produced as antibodies, fragments of thereof, or fusion proteins with another proteins and the fragments, by using the expression vector made by gene rearrangement using the cDNA separated from antibody-producing hybridoma.

[0016] The membrane protein on cell membrane of human PD-1-expressing cells means the membrane protein that expresses on cell membrane of the same cell as human PD-1-expressing cells, and includes each the membrane protein of human PD-1-expressing human first stage culture cells or human cell lines. For example, T cell receptor complex or B cell receptor complex is preferable.

[0017] The part that recognizes the membrane protein on cell membrane of human PD-1-expressing cells may be a substance that recognizes the membrane protein that expresses on cell membrane of the same cell as human PD-1-expressing cells, and includes, for example, antibodies against the membrane protein and fragments thereof, the membrane protein itself and fragments thereof, ligands for the membrane protein and fragments thereof, and low molecular weight organic compounds that bind to the membrane protein *etc.*

[0018] The antibodies or partial fragments thereof to the membrane protein on cell membrane of human PD-1-expressing cells are antibodies or partial fragments thereof to the membrane protein that expresses on cell membrane of the same cell as human PD-1-expressing cells, and may be either of complete polyclonal or monoclonal antibodies, humanized antibodies, complete human antibodies, and short antibodies thereof (for example, F(ab')₂, Fab', Fab, Fv) *etc.*

[0019] T cell receptor complex is at least a complex comprising T cell receptor consisting of α subunit and β subunit and CD3 consisting of γ subunit, δ subunit, ϵ subunit, and ζ subunit.

[0020] B cell receptor complex is at least a complex comprising membrane-bound immunoglobulin, CD79 α subunit, and CD79 β subunit.

[0021] The antibodies or partial fragments thereof to T cell receptor complex may be either of antibodies or partial fragments thereof that recognize T cell receptor complex. They include antibodies or partial fragments thereof to each subunit of T cell receptor and CD3, which composes T cell receptor complex and may be either of complete polyclonal or monoclonal antibodies, humanized antibodies, complete human antibodies, and short antibodies thereof (for example, F(ab')₂, Fab', Fab, Fv) *etc.* For example, the monoclonal antibodies against CD3 can be produced by using hybridoma that has already been established. Anti-CD3 (α -CD3 ϵ mAb (PharMingen, Inc.)) can be bought.

[0022] The antibodies or partial fragments thereof to B cell receptor complex may be either of antibodies or partial fragments thereof that recognize B cell receptor complex. They include antibodies or partial fragments thereof to each

subunit of membrane-bound immunoglobulin and CD79, which composes B cell receptor complex, and may be either of complete polyclonal or monoclonal antibodies, humanized antibodies, complete human antibodies, and short antibodies thereof (for example, $F(ab')_2$, Fab', Fab, Fv) etc. Concretely, commercial anti-BCR antibodies can be used and, for example, anti-IgG (H+L) polyclonal antibodies can be bought (Zymed Laboratories).

[0023] The substance comprising the part that recognizes human PD-1 and the part that recognizes the membrane protein on cell membrane of human PD-1-expressing cells means a substance that can simultaneously bind to an extracellular domain of human PD-1 and an extracellular domain of the membrane protein on cell membrane of the same cell. Concretely, they include bispecific antibodies comprising specific antibodies or fragments thereof to human PD-1 and specific antibodies or fragments thereof to the membrane protein on cell membrane of human PD-1-expressing cells.

[0024] The bispecific antibodies are unsymmetrical antibodies having two independent antigen-recognition sites with two different antigenic specificities. A well-known chemical method (Nisonoff, A., *et al.*, *Archives of Biochemistry and Biophysics*, 90;460-462 (1961), Brennan, M., *et al.*, *Science*, 299;81-83 (1985)) is already well-known as a preparation method of the bispecific antibodies. The bispecific antibodies can be obtained by respectively hydrolyzing two kinds of antibodies by enzyme and cutting disulfide bonds of the H chains by reducing agents, and then mixing and reoxidizing the different kind of antibodies. Recently, the preparation method using cross linking agents such as glutaraldehyde and carbodiimide has been disclosed (JP02-01556).

[0025] Technologies that directly produce the bispecific antibodies by using gene recombination technologies have been known. For example, the producing of bispecific antibodies (called single chain diabody) to carcinoembryonic antigen and *E. coli* beta-galactosidase has been reported in Alt, *FEBS Letter*, 454, 90 (1999). A heavy chain variable domain (VH) and other light chain variable domain (VL) of the fragment are connected with linkers to make them combine between two continuous domains on the same chain. A heavy chain variable domain (VH) and other light chain variable domain (VL) of the fragment are connected with linkers to make them combine between two continuous domains on the same chain. Therefore, VH and VL domain of the fragment are unavoidable to combine with complementary VL and VH domain of another fragment, as a result, two antigen binding sites are formed. Though 3-12 amino acid residues are preferable for the peptide linkers, the sequence is not limited (Hudson, P.J., *et al.*, *Journal of Immunology Medicine*, 231, 1-2; 177-189 (1999)).

[0026] As manufacturing of the bispecific antibodies using hybridomas, there is Reading, *et al.*'s method, that is, a method of producing hybrid hybridomas by further fusing two kinds of hybridomas that produce the monoclonal antibodies and then selecting hybrid hybridomas that produce target bispecific antibodies (US4474893).

[0027] The bispecific antibodies comprising specific antibodies or fragments thereof to human PD-1 and specific antibodies or fragments thereof to the membrane protein on cell membrane of human PD-1-expressing cells are antibodies that can simultaneously bind to the extracellular domain of human PD-1 and the extracellular domain of the membrane protein on cell membrane of the same cell.

[0028] The bispecific antibodies can be produced by the following method;

- (1) animals are sensitized by human PD-1 or human membrane protein as an immunogen,
- (2) splenic cells from the sensitized animals and myeloma cells from syngeneic animals are fused,
- (3) cells that produce monoclonal antibodies against the sensitizing antigen (human PD-1 or human membrane protein) are screened from the obtained hybridomas,
- (4) target antibodies-producing hybridomas are cloned,
- (5) the cloned antibodies-producing hybridomas are proliferated,
- (6) the produced antibodies are separated and refined,
- (7) the bispecific antibodies are produced by cross-linking the obtained anti-human PD-1 antibodies and anti-human membrane protein antibodies with linkers, or
- (8) they are further digested by pepsin and are separated, and refined to obtain $F(ab')_2$,
- (9) each prepared $F(ab')_2$ is reduced and is separated and refined,
- (10) the bispecific antibodies can be produced by cross-linking each prepared Fab_{SH} by linkers.

The linkers are not limited and may be anything that can link the part that recognizes the membrane protein of PD-1-expressing cells to the part that recognizes human PD-1, keeping an appropriate range. More concretely, they include peptides and amides etc.

The commercial products, for example, phenylenedimaleimide (Aldrich) can be used as the linkers.

When both or one of substances that respectively recognize the membrane protein of PD-1-expressing cells and human PD-1 is/are low-molecular weight organic compound(s),

- (11) using the antibodies produced by the above technique, the low-molecules that inhibit a bond between human membrane protein or human PD-1 and each antibody are found by measuring with a suitable detector,
- (12) the antibody can be produced by cross-linking the low-molecules, the antibodies, or the Fab with linkers.

[0029] It concretely explains each process as follows.

[0030] (1) In sensitization, it is preferable that human PD-1 or human membrane protein is administrated to peritoneal cavity or foot pat of sensitized animals. And, the sensitized animals have only to be animals such as mouse and rat etc. that the monoclonal antibody can be obtained in general and are not limited. For example, it is enough that 10-200

5 μg of the antigen are administrated to mouse once.

[0031] A spleen of the sensitized animal that antibody titer has risen enough among the sensitized animals in previous (1) is removed. Suspension of the splenic cells is prepared according to the usual manner. Then, cell fusion of previous (2) is performed by adding polyethylene glycol (preferably PEG4000.) to the mixture with the obtained splenic cells and syngeneic myeloma cells at 37°C. Several kinds such as P3 \times 63Ag8, P3/NS1/1-Ag4-1, and SP-2/0-Ag-14 are

10 known as mouse myeloma cells, and everything are obtained easily.

[0032] It is preferable that myeloma cells are HGPRT (hypoxanthine-guanine phosphoribosyltransferase)- cell lines that can not live in HAT media (a medium containing hypoxanthine, aminopterin, and thymidine), and don't secrete antibodies. SP-2/0-Ag-14 are preferably used.

[0033] Then, the obtained cell fusion mixtures are sown in 96 microwell plate at low density, which are cultured in HAT medium. By 1-2 weeks, unfused myeloma cells, hybridomas of myeloma cells, unfused splenic cells, and hybridomas of splenic cells die out, whereas only hybridomas of splenic cells and myeloma cells proliferate.

[0034] By reacting culture supernatant of hybridomas with solid phase antigens and measuring the antibodies that specifically adsorbs the antigens by using labeled second antibodies, screening of previous (3) judges whether hybridomas product the antibodies against human membrane protein or human PD-1 or not.

20 [0035] The process of (4) is performed by cloning antibody-producing hybridomas according to soft agar culture (*Monoclonal Antibodies*, 372 (1980)). In this case, it is also possible to use the limiting dilution.

[0036] In the process of (5), to obtain a large amount of antibody more efficiently, a method of administrating the hybridomas into mouse peritoneal cavity, and separating and refining them from peritoneal fluid can be used.

25 [0037] In the process of (6), usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. are used, and more effectively, affinity chromatography using protein A-sepharose CL-4B (Amersham Biosciences K.K.) can be used.

[0038] Since the bispecific antibodies of the present invention specifically bind, they can be used for purification and concentration such as affinity chromatography etc. of human PD-1.

30 [0039] In the process of (7), for example, cross linking agents can make sulfo-EMCS (N-(6-maleinimidecapoxy) succinimide sodium salt) bind to SH (mercapto) groups or amide groups of antibodies. First, either of antibodies is referred to amido coupling reactions with sulfo-EMCS. The unreacted sulfo-EMGS is separated by gel filtration. SH (mercapto) groups of the other antibody that have been reduced by 2-mercaptoethylamine etc. are referred to react with maleimide groups of sulfo-EMCS that have bound to the first antibody. The one that two kinds of antibodies were mutually cross-linked is separated by gel filtration.

35 [0040] In the process of (8), each antibody that be obtained in process (6) was digested by pepsin for 48 hours at 37°C. F(ab')₂ digested by pepsin are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. and more effectively, gel filtration using cefaclor S-200 (Amersham Biosciences K.K.) can be used.

40 [0041] In the process of (9), F(ab')₂ are reduced by 2-mercaptoethanol for 30 minutes at 30°C. The reduced Fab_{SH} are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. and more effectively, gel filtration using cefaclor S-200 can be used.

[0042] In the process of (10), the other antibodies in Fab_{SH} fraction are referred to bind with linkers. Cross linking agents have only to bind mercapto (SH) groups of Fab_{SH}, which is referred to react with phenylenedimaleimide for 30 minutes at room temperature. Then, it is referred to react with 1.3 times more the other Fab_{SH} for 4 hours at room

45 temperature. The obtained substance having bivalent specificity are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. and more effectively, gel filtration using cefaclor S-200 can be used.

[0043] In the process of (11), the antibodies obtained in process (6) can be used as they are, or as the one that are preferably labeled (for example, biotin-labeling and FITC-labeling etc.) by the common procedure. In ELISA, the antibodies are added to solid phase antigens. Then, when using enzyme-labeled secondary antibody and biotin-labeled antibody, the specific binding between the antibodies and the antigens can be measured by absorptiometer under the presence of chromophore substance, after adding enzyme-labeled streptavidin. Low-molecules that specifically recognize PD-1 or the membrane protein can be obtained by using this assay system.

50 [0044] In the process of (12), when the other is an antibody or Fab, it can bind to an antibody or Fab by introducing suitable functional groups to the obtained low-molecules. For example, if maleimide groups are introduced, it can bind to mercapto (SH) groups of the antibody or Fab. If both are low-molecules, molecules including both can be synthesized.

[0045] On the other hand, cDNA of each antibody can be separated from hybridomas that produce the monoclonal antibodies against each antigen. By transforming suitable host cells using expression vector containing DNA that both

cDNA or partial fragments thereof have been linked by gene recombination methods, the host cells can produce bispecific antibodies.

[0046] Concretely, the bispecific antibodies comprising the antibodies against human PD-1 or partial fragments thereof and the antibodies against the membrane protein on cell membrane of human PD-1-expressing cells or partial fragments thereof can be prepared by the following methods;

- (1) Each antibody gene is separated from each hybridoma that anti-human PD-1 monoclonal antibodies and anti-membrane protein monoclonal antibodies are respectively produced,
- (2) Variable region DNA of anti-human PD-1 monoclonal antibody gene and variable region DNA of anti-membrane protein monoclonal antibody gene are linked by using linker DNA. The expression vectors containing the linked DNA fragments are introduced to suitable host cells,
- (3) the cells are cultured under a suitable culture condition, and produced proteins are separated and refined.

[0047] Each process is concretely explained as follows.

[0048] The process of (1) comprises a process of separating RNA from hybridomas and a process of separating an antibody gene or cDNA encoding partial peptide thereof.

[0049] The process of separating the total RNA or mRNA from hybridomas can be performed according to a well-known method (a method described in Sambrook, J., *et al.*, *Molecular Cloning* (1989), Cold Spring Harbor Laboratory, or F. M. Ausubel., *et al.*, *Current Protocol in Molecular Biology*).

[0050] By using synthetic DNA primers having partial nucleotide sequences of the antibodies of the present invention, cDNA encoding the antibody genes of the present invention or partial peptide thereof can be amplified by Polymerase Chain Reaction (hereafter, called PCR). Or, by hybridization with probes labeled by using DNA fragments or the synthetic DNAs encoding a part or whole region of the antibodies of the present invention, the cDNA can be selected from cDNA contained in suitable vectors. The hybridization can be performed according to a well-known method. The antibody gene can be amplified by using the total RNA or mRNA by Reverse Transcriptase Polymerase Chain Reaction (Hereafter, called RT-PCR).

[0051] (2) As a method of producing the bispecific antibodies of the present invention,

(i) a method of synthesizing peptide and

(ii) a method of producing by gene recombination technologies *etc.* are enumerated, and the method of the described in (ii) is preferable, industrially.

[0052] The expression system (hosts-vector system) to produce peptide by using gene recombination technologies includes, for example, the expression system of bacillus, yeasts, insect cells, and mammalian cells.

[0053] The vector system includes *E. coli* plasmids (for example, pBR322, pBR325, pUC12, and pUC13), *Bacillus subtilis* plasmids (for example, pUB110, pTP5, and pC194), yeast plasmids (for example, pSH19 and pSH15), bacteriophages such as lambda phage, animal viruses such as retrovirus, vaccinia virus, and baculovirus, PA1-11, pXT1, pRc/CMV, pRc/RSV, and pcDNA1/Neo *etc.*

[0054] The promoter in the present invention has only to be an appropriate promoter corresponding to the gene expression host. For example, when animal cells are used as hosts, SR α promoter, SV40 promoter, LTR promoter, CMV promoter, and HSV-TK promoter *etc.* are enumerated. It is preferable to use CMV (cytomegalovirus) promoter, SR α promoter *etc.* In case of *Escherichia coli*, trp promoter, lac promoter, recA promoter, λ PL promoter, lpp promoter, and T7 promoter *etc.* are preferable. In case of *Bacillus* bacterium, SPO1 promoter, SPO2 promoter, and penP promoter *etc.* are preferable. In case of yeasts, PHO5 promoter, PGK promoter, GAP promoter, and ADH promoter *etc.* are preferable.

[0055] Additionally, the expression vector containing enhancer, splicing signal, polyA signal, selected marker, and SV40 duplication ori (hereafter, it may be called SV40ori.) *etc.* can be used, if necessary. The selected marker includes, for example, dihydrofolate reductase (hereafter, it may be called dhfr.) gene (Methotrexate (MTX) resistance), ampicillin resistance gene (hereafter, it may be called Amp^r), and neomycin resistance gene (hereafter, it may be called Neor. G418 resistance) *etc.* Especially, when dhfr gene is used as a selected marker using dhfr gene deficient chinese hamster cells, a target gene can be selected even by using the medium without thymidine. The signal sequence to suitable for the hosts can be added to N-terminal side of the protein of the present invention, if necessary. When the hosts are *Escherichia*, PhoA signal sequence and OmpA signal sequence *etc.* can be used. When the hosts are bacillus, α -amylase signal sequence and subtilisin signal sequence *etc.* can be used. When the hosts are bacillus, MF α signal sequence, SUC2 signal sequence *etc.* can be used. When the hosts are animal cells, α -insulin signal sequence, α -interferon signal sequence, and antibody signal sequence *etc.* can be used, respectively. The transformants can be manufactured using the vector containing DNA encoding the constructed protein of the present invention.

[0056] By culturing *Escherichia* transformed with the expression vector in suitable medium, the target peptide is

obtained from the body cells. And, if a signal peptide (for example, a signal peptide of pelB) of bacteria is used, the target peptide is secreted in the periplasm. Further, it can be produced as fusion protein with other peptide. In case of the expression in mammalian cells, for example, by culturing mammalian cells transformed by suitable expression vectors including cDNA encoding a target protein in suitable medium, the target peptides are secreted into medium.

[0057] For example, *Escherichia*, *Bacillus* bacterium, yeasts, insect cells, insects, and animal cells *etc.* can be used as host cells. For example, *Escherichia coli* K12, DH1, JM103, JA221, HB101, C600, JM109, DH5, and DH5 α *etc.* can be used as concrete examples of *Escherichia*. For example, bacillus *Bacillus subtilis* MI114 *etc.* can be used as *Bacillus* bacterium. For example, *Saccharomyces cerevisiae* AH22, AH22R - NA87-11A, DKD-5D, or 20B-12, *Saccharomyces pombe* NCYC1913, or NCYC2036, and *Pichia pastoris* KM71 *etc.* can be used as yeasts. When virus is AcNPV, for example, *Spodoptera frugiperda* Cell (SF cell), MG1 cells derived from *Trichoplusia ni* midgut, High FiveTM cells derived from *Trichoplusia ni* egg, cells derived from *Mamestra brassicae*, cells derived from *Estigmene acrea* *etc.* can be used as insect cells. When virus is BmNPV, cell lines derived from silkworm (*Bombyx mori* N cells; BmN cells) *etc.* can be used. For example, Sf9 cells (ATCC CRL1711) (Vaughn, J. L., *In Vivo*, 13; 213-217 (1977)) and Sf21 cells *etc.* can be used as Sf cells. For example, silkworm larvae *etc.* can be used as insects. For example, COS-1, COS-7, Vero, chinese hamster cell CHO (hereafter, it's abbreviated with CHO cells.), dhfr-deficient chinese hamster cell CHO (hereafter, it's abbreviated with CHO(dhfr-) cells), mouse L cells, mouse AtT-20, mouse myeloma cells, rat GH3, HEK293 T lymphocytes, and human FL cells *etc.* can be used as animal cells. For example, *Escherichia* transformation can be performed according to *Proc. Natl. Acad. Sci. (USA)*, 69, 2110 (1972). For example, *Bacillus* transformation can be performed according to *Molecular & General Genetic*, 168, 111 (1979). For example, yeasts transformation can be performed according to Becker, DM., *et al*, *Methods in Enzymology*, volume 194, p.182-187 (1991), or *Proc. Natl. Acad. Sci. (USA)*, 75, 1929 (1978). Insect cells or insects transformation can be performed according to *Bio Technology*, 6; 47-55 (1978). Animal cells transformation can be performed according to *CELL TECHNOLOGY SUPPLEMENT 8 NEW CELL TECHNOLOGY EXPERIMENTAL PROTOCOL*, Shujunsha, 263 (1995), or *Virology*, 52, 456 (1973).

[0058] (3) The obtained peptides are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography *etc.*

[0059] In general, a substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide containing the amino acid sequence that is 90% or more, 95, 98, or 99% or more homologous to the polypeptide on producing.

[0060] A homologue of the substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide containing the amino acid sequence that is at least 70% or more, preferably at least 80, 90, or 95% or more homologous to the polypeptide over a region of at least continuous 20 amino acids, preferably at least 30, 40, 60, or 100 amino acids.

[0061] A fragment of the substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide containing at least 10 amino acids, preferably at least 15, 20, 25, 30, 40, 50, or 60 amino acids, and a homologue thereof is a polypeptide containing the amino acid sequence that is at least 70%, preferably at least 80, 90, or 95% or more homologous to the polypeptide over a region of at least continuous 10 amino acids, preferably at least continuous 15, 20, 25, 30, 40, 50, or 60 amino acids.

[0062] A substantially pure polypeptide comprising amino acid sequence that deleted one or several amino acids from a polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide comprising amino acid sequence that deleted one or two amino acids or more (preferably 1 to approx. 25, more preferably 1 to approx. 10, furthermore, preferably 1 to 5) from amino acid sequence.

[0063] A substantially pure polypeptide comprising amino acid sequence that has been substituted by one or several amino acids from a polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide comprising amino acid sequence that has been substituted by one or two amino acids or more (preferably 1 to approx. 25, more preferably 1 to approx. 10, furthermore, preferably 1 to 5).

[0064] A homologue of a polynucleotide comprising DNA the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:9 is a polynucleotide that is at least 70%, preferably at least 80, 90, or more preferably 95% or more homologous to the polynucleotide over a region of at least continuous 20, preferably at least continuous 30, 40, 60, or 100 nucleotide sequence.

[0065] A fragment of the polynucleotide comprising DNA the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:9 is a polynucleotide containing polynucleotide comprising at least continuous 20, preferably at least continuous 30, 40, 50, 60, or 100 nucleotide sequence.

[0066] A DNA hybridizing to DNA containing the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:9 under stringent condition includes, for example, approx. a DNA containing nucleotide sequence that is approx. 70% or more, preferably approx. 80% or more, more preferably approx. 90% or more, most preferably approx. 95% or more homologous to nucleotide sequence respectively represented by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9.

[0067] The hybridization can be performed according to a well-known method or, for example, a method described

in J. Sambrook, *Molecular Cloning*, 2nd, Coldspring Harbor Laboratory. When using a commercial library, it is possible to perform it according to an attached method described in directions for use. More preferably, it is possible to perform it under stringent condition. High-stringent condition is approx. 19-40 mM, preferably approx. 19-20 mM of NaCl concentration, at approx. 50-70°C, preferably approx. 60-65°C. Approx. 19 mM of sodium concentration at approx. 65°C is most preferable, especially.

Industrial applicability

Application to medicine:

[0068] The substance specific to human PD-1 of the present invention can be used for therapy and/or prevention for the following disease.

[0069] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for neurodegenerative diseases (geriopsychosis, Alzheimer disease, Down syndrome, Parkinson's disease, Creutzfeldt-jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt-Jakob disease).

[0070] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for diseases that accelerate the immune reaction, for example, autoimmune diseases (glomerular nephritis, arthritis, dilated cardiomyopathy-like disease, ulcerous colitis, Sjogren syndrome, Crohn disease, systemic erythematodes, chronic rheumatoid arthritis, multiple sclerosis, psoriasis, allergic contact dermatitis, polymyositis, pachyderma, periarteritis nodosa, rheumatic fever, vitiligo vulgaris, insulin dependent diabetes mellitus, Behcet disease, Hashimoto disease, Addison disease, dermatomyositis, myasthenia gravis, Reiter syndrome, Graves' disease, anaemia perniosa, Good-pasture syndrome, sterility disease, chronic active hepatitis, pemphigus, autoimmune thrombopenic purpura, and autoimmune hemolytic anemia).

[0071] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for collagenosis (systemic lupus erythematosus, rheumatoid arthritis, systemic scleroderma, diffuse scleroderma, dermatomyositis, polymyositis, polymyositis, Sjogren's syndrome, mixed connective tissue disease, polyarteritis nodosa, and rheumatic fever *etc.*).

[0072] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for organ graft rejection, allergic disease, and diseases caused by attenuation of immune reaction, which PD-1 participates, for example, tumour and infectious disease.

[0073] When using the substance specific to human PD-1 of the present invention for the above purpose, it is usually administered systemically or locally, and orally or parenterally.

[0074] The dosage is different depending on age, body weight, symptom, therapeutic effect, administration route, and duration of the treatment *etc.* For oral administration, generally, the dosage range from 0.1 mg to 100 mg per an adult is orally administered once to several times per day, or the dosage range from 0.01 mg to 30 mg per an adult is administered once to several times per day parenterally, suitably intravenously, and is intravenously administered for 1 to 24 hours per day continuously.

[0075] Since the dosage changes depending on various conditions as described above, there are cases in which doses lower or greater than the above dosage may be used.

[0076] When a composition of the present invention is administered, it is used as internal solid medicines and internal liquid medicines for internal use, and injections, external preparations, suppositories *etc.* for parenteral administration.

[0077] The internal solid medicines for oral administration include compressed tablets, pills, capsules, dispersing powders, granules *etc.* The capsules include hard capsules and soft capsules.

[0078] In case of such the solid medicines, one or more active compound(s) may be pharmaceutically manufactured as itself/themselves or a formulation with excipients (lactose, mannitol, glucose, microcrystal cellulose, and starch *etc.*), binders (hydroxypropylcellulose, polyvinyl pyrrolidone, and magnesium metasilicate aluminate *etc.*), disintegrators (cellulose calcium glycolate *etc.*), lubricants (magnesium stearate *etc.*), stabilizers, or solubilizers (glutamate and aspartic acid *etc.*) *etc.* according to usual methods. Further, they may be optionally coated by coatings (sucrose, gelatin, hydroxypropylcellulose, and hydroxypropylmethylcellulose phthalate *etc.*) or coated in the layer of two or more. Further, capsules of absorbable materials such as gelatin may be included.

[0079] The liquid compositions for oral administration include pharmaceutically acceptable waters, suspensions, emulsions, syrups, and elixirs *etc.* As to such liquid medicines, one or more active compound(s) may be dissolved, suspended, or emulsified to generally used diluent (purified water, ethanol or those mixing liquids *etc.*). Further, those liquid medicines may contain humectants, suspending agents, emulsifying agents, sweeteners, flavor agents, flavoring agents, preservatives, and buffers *etc.*

[0080] The injections for parenteral administration include solid injections that are dissolved or suspended to solution, suspension, emulsion, or time of use solvent. The injections are used by dissolving, levigating and melting one or more

activator(s) to the solvent. As the solvent, for example, water for injection, distilled saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol *etc.* and these combinations are used. Further, this injection may include stabilizers, solubilizers (glutamate, aspartic acid, and polysorbate 80 (registered trademark) *etc.*), suspending agents, emulsifying agents, soothing agents, buffers, and preservatives *etc.* These are sterilized in the final process or are manufactured from the aseptic manipulation. Aseptic solid medicines may be manufactured as a freeze-drying product and may be used by making to be aseptic or dissolving to aseptic distilled water for injection or other solvents before use.

[0081] Other compositions containing one or more activator(s) for parenteral administration include liquid for external use, ointment drug, coating drug, inhalant, aerosol, suppository and pessary for intrarectal administration which is prescribed according to a routine procedure.

[0082] The sprays may contain a stabilizer such as sodium hydrogen sulfite besides the diluent generally used, a buffer giving isotonicity, and an isotonic medicine such as, for example, sodium chloride, sodium citrate, or citrates. Production methods of the sprays have been described in, for example, U.S. Patent 2,868,691 specification and U.S. Patent 3,095,355 specification in detail.

[0083] Since PD-1 relates to the immune reaction, PD-1 can also be used for screening *etc.*, the substance related to the immune reaction by measuring the expression of human PD-1 using the substance specific to human PD-1 of the present invention.

[0084] The substance specific to human PD-1 of the present invention comprises of a part that recognizes human PD-1, a part that recognizes the membrane protein on cell membrane of human PD-1-expressing cells, and a linker, and is an excellent substance that specifically recognizes human PD-1 and the membrane protein, and can transmit human PD-1 signal.

Brief Description of Drawings

[0085]

Figure 1 shows the construction of a bispecific antibody expression vector.

Figure 2 shows the reactivity of each bispecific antibody against X63 cell surface antigen expressed in CD3(-)/PD-1(+) cells and peripheral blood mononuclear cells (PBMC) surface antigen as CD3(+)/PD-1(-) cells. In this figure, filling areas of histogram represent control IgG and opening areas represent distribution of PD-1 or CD3 positive cell.

Figure 3 shows the effect on proliferative response of activated human peripheral blood T cells of bispecific antibody. In this figure, "-" represents Control IgG-adding group and "BsAb" represents the bispecific antibody-adding group, the spindle represents measurement absorbance, and ** represents $P < 0.05$ in significance test.

Best Mode for Carrying out the Invention

[0086] The following examples explain the present invention more concretely, but don't limit the range of the present invention.

Example 1:

[0087] To obtain DNA encoding anti-human PD-1 antibody and anti-human CD3 antibody respectively, each total RNA was isolated from J110 (International Trust Number: FERM BP-8392) hybridoma and CD3 antibody hybridoma (obtained from ATCC : ATCC Number: CRL-8001). The operation was performed by using SV total Isolation System (trade name: purchase from Promega) according to the manufacturer instructions.

[0088] J110 hybridoma cDNA library and CD3 antibody hybridoma cDNA library were generated from total RNA (total RNA) by oligo dT prime method by using Ready-To-Go You-Prime First-Strand Beads (trade name: purchase from Amersham Pharmacia). The operation and procedure were done according to the manufacturer instructions.

[0089] cDNA of variable region of each IgG heavy chain and IgG light chain of anti-human PD-1 antibody and anti-human CD3 antibody was amplified by PCR reaction using Heavy Primers and Light Primers (the trade name: purchase from Amersham Pharmacia), respectively. PCR was carried out the following steps; as a first step at 95°C for 2 minutes and as cycle steps at 95°C for 30 seconds, at 50°C for 30 seconds, and at 72°C for 40 seconds was repeated 30 times and was left at 72°C for 5 minutes as last step.

[0090] PCR product was separated by agarose gel electrophoresis. The expected size of DNA fragment was collected and was cloned into pGEM-T Easy Vector (trade name: purchase from Promega). Then, *E. coli* DH5 α was transformed with the plasmid. DNA of each IgG heavy chain (SEQ ID NO:1 or 5) and IgG light chain (SEQ ID NO:3 or 7) were sequenced to determine the consensus sequence.

Example 2:

[0091] DNAs encoding bispecific antibodies were prepared by being respectively connected to the separated cDNAs in example 1. Fragment 1 was prepared by connecting IgG heavy chain cDNA (SEQ ID NO:1) of anti-human PD-1 antibody and IgG light chain cDNA (SEQ ID NO:7) of anti-human CD3 antibody by PCR using linker No.1 (SEQ ID NO:19), linker No.2 (SEQ ID NO:20), primer No.1 (SEQ ID NO:14), and primer No.2 (SEQ ID NO:15) (Figure 1). Fragment 2 was prepared by connecting IgG heavy chain cDNA (SEQ ID NO:7) of anti-human CD3 antibody and IgG light chain cDNA (SEQ ID NO:1) of anti-human PD-1 antibody by PCR using linker No.3 (SEQ ID NO:21), linker No.4 (SEQ ID NO:22), primer No.3 (SEQ ID NO:16), and primer No.4 (SEQ ID NO:17) (figure.1). Fragment 3 was prepared (Figure 1) by connecting fragment 1 and fragment 2 by PCR using linker No.5 (SEQ ID NO:23), linker No.6 (SEQ ID NO:24), primer No.5 (SEQ ID NO:18), and primer No.4 (SEQ ID NO:22) and then the nucleotide sequence was decided (SEQ ID NO:9).

[0092] Each PCR reaction was respectively performed. First PCR was performed by repeating 20 times the following steps; at 94°C for 30 seconds, at 40°C for 30 seconds, and at 72°C for 50 seconds. 2nd PCR was performed by repeating 30 times the following steps; at 94°C for 30 seconds, at 50°C for 30 seconds, and at 72°C for 50 seconds, by using first PCR solution as a template.

Primer No.2:

5'-TTTTTTAAGCTTACAGGTCCAGCTGCAGGAGTCA-3' (SEQ ID NO:14)

Primer No.2:

5'-TTTTTTGCGGCCGCCCGGTTTATTTCCAACCTTTG-3' (SEQ ID NO:15)

Primer No.3:

5'-TTTTTTAAGCTTACAGGTCCAGCTGCAGCAGTCT-3' (SEQ ID NO:16)

Primer No.4:

5'-TTTTTTGCGGCCGCCCGTTTGATTTCCAGCTTGG-3' (SEQ ID NO:17)

Primer No.5:

5'-ATGAACTGGTACCAGCAGAAG-3'(SEQ ID NO:18)

Linker No.1:

5'-AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTACAAAATTGTT
CTCACCCAGTCTCCAG-3' (SEQ ID NO:19)

Linker No.2:

5'-CTGGAGACTGGGTGAGAACAATTTGTGAACCGCCTCCACCTGAGGAGAC
GGTGACCGTGGTCCCT-3' (SEQ ID NO:20)

Linker No.3:

5'-AGGCACCACTCTCACAGTCTCCTCAGGTGGAGGCGGTTTCAGACATCCAG
ATGACCCAGTCTCCAG-3' (SEQ ID NO:21)

Linker No.4:

5'-CTGGAGACTGGGTCATCTGGATGTCTGAACCGCCTCCACCTGAGGAGAC
TGTGAGAGTGGTGCCT-3' (SEQ ID NO:22)

Linker No.5:

5'-GGGGACAAAGTTGGAAATAAACCGGGGTGGAGGCGGTTTCAGGCGGAGGT
GGCTCTGGCGGTGGCGGATCGCAGGTCCAGCTGCAGCAGTCTGGGG-3' (SEQ ID
NO:23)

Linker No.6:

5'-CCCCAGACTGCTGCAGCTGGACCTGCGATCCGCCACCGCCAGAGCCACC
TCCGCCTGAACCGCCTCCACCCCGGTTTATTTCCAACTTTGTCCCC-3' (SEQ ID
NO:24)

[0093] DNA encoding the bispecific antibody prepared by the above method was cloned into expression vector pSecTag2/HygroA (trade name: purchase from Invitrogen). First, each of fragment 1 and fragment 3 was digested by restriction enzyme *HindIII*, *KpnI*, *KpnI*, and *NotI* and then was purified by agarose electrophoresis. Then, the DNA fragments were ligated in a *HindIII* and *NotI* digested pSecTag2/HygroA vector. *E. coli* DH5 α was transformed with the plasmid J110-CD3scDb-pSec/hygroA encoding the bispecific antibody was amplified, extracted, and purified (Figure 1).

Example 3:

[0094] Bispecific antibody protein was prepared by J110-CD3scDb-pSec/hygroA expression plasmid. The construct was transiently transfected into human kidney cell line 293T (ATCC Number: CRL-11268) with LipofectAMINE-plus (trade name: purchased from Invitrogen) and cultured for four days. The supernatant was sterilized with 0.22 μ m PVDF filter, and was concentrated using 40% PEG20000 solution. The concentrated supernatant was purified by HiTrap Cheating HP column (trade name: purchased from Amershampharmacia).

Example 4:

[0095] The reactivity of the bispecific antibody (PD-1 and CD3) binding to cell surface antigens analyzed by FACScan.

[0096] 1 or 10 µg of the bispecific antibodies were respectively added to human PD-1-expressed X63 cell lines as PD-1 positive/CD3 negative cells (CD3(-)/PD-1(+) cells) and human peripheral blood mononuclear cells as PD-1 negative/CD3 positive cells (CD3(+)/PD-1(-) cells), and incubated on ice. Immediately second antibodies were added and incubate on ice for 30 min. It was confirmed that the bispecific antibodies reacted to PD-1 and CD3.

Example 5:

[0097] The activity of the bispecific antibody was evaluated as an effect on the proliferation of activated human peripheral blood T cells.

[0098] Concretely, PBMC were isolated from peripheral blood samples of healthy donors by Lymphoprep Tube (trade name: purchased from HYCOMED PHARMA). The operation and procedure were done according to the manufacturer instructions. Erythocytes were removed from PBMC by lysis with lysis buffer (0.8% NH_4Cl , 0.1% KCO_3 , 1 mM EDTA). And purified T cell passed through Nylon Fiber ColumnT (trade name: purchased from Rosh) were resuspended to medium (RPM11640 medium including 10% fetal bovine serum).

[0099] Purified T cell ($2 \times 10^6/\text{mL}/\text{well}$) were cultured for 60 hours with 1 µg/ml anti-human CD28 antibody (the clone name: CD28.2 and purchased from Pharmingen) in 24 well-plate that has were pre-coated with 5 µg/ml anti-human $\alpha\beta\text{TCR}$ antibody (the clone name: T10B9.1A-31 and purchased from Pharmingen). Activated T cells were rested for 12 hours, and resting T cells ($1 \times 10^6/100 \mu\text{l}/\text{well}$) were restimulated adding 1 µg/well of bispecific antibody in 96 well-plate that were pre-coated with 0.1 µg/ml anti- $\alpha\beta\text{TCR}$ antibody. 48 hours later, T cell proliferation was determined=by BrdU incorporation using Cell Proliferation ELISA (the trade name: purchased from Rosh). Figure 3 shows the result.

[0100] The bispecific antibodies have significantly decreased the proliferation of the activated human peripheral blood T cells.

SEQUENCE LISTING

<110> ONO PHARMACEUTICAL CO., LTD.
HONJO, Tasuku

5 <120> Substances which specifically recognize human PD-1
<130> ONF-4846PCT
<150> JP 2003-14793
<151> 2003-01-23
<160> 26
<170> PatentIn version 3.1

10 <210> 1
<211> 357
<212> DNA
<213> Mus musculus

15 <400> 1
cagggtccagc tgcaggagtc aggacctggc ctgggtgaaac cttctcagtc tctgtccctc 60
acctgcactg tcactggcca ctcaatcacc agtgattatg cctggaactg gatccggcag 120
tttccaggag acaaaactgga gtggatgggc tacataagct acagtgggta cactacctac 180
aaccatctc tgaaaagtcg agtctctatc actcgagaca catccaagaa ccagttcttc 240
ctgcagttga attctgtgac tactgaggac acagccacat acttctgtgc aagagacctt 300
gattacggcc cctgggtttgc ttactggggc caagggacca cggtcaccgt ctcctca 357

20 <210> 2
<211> 119
<212> PRT
<213> Mus musculus

25 <400> 2
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Ser Leu Ser Leu Thr Cys Thr Val Thr Gly His Ser Ile Thr Ser Asp
20 25 30
Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asp Lys Leu Glu Trp
35 40 45
30 Met Gly Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser Leu
50 55 60
Lys Ser Arg Val Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
65 70 75 80
Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
35 Ala Arg Asp Leu Asp Tyr Gly Pro Trp Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser
115

40 <210> 3
<211> 324
<212> DNA
<213> Mus musculus

45 <400> 3
gacatccaga tgacccagtc tccagcctcc ctatctgcat ctgtgggaga aactgtcacc 60
ctcacatgtc gagcaagtga gaattattac aattatttag catggtatca gcagaaacag 120
ggaaaatctc ctcagctcct ggtctataat gtaaaaacct tagcagatgg tgtgccatca 180
aggttcagtg gcagtggatc aggaacacaa tattctctca agatcaacag cctgcagcct 240
gaagattttg ggagtiatta ctgtcaacat ttttgagta gtccgtggac gttcgggtgga 300
ggcaccaagc tggaaatcaa acgg 324

50 <210> 4
<211> 108
<212> PRT
<213> Mus musculus

55 <400> 4
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly

1 5 10 15
 Glu Thr Val Thr Leu Thr Cys Arg Ala Ser Glu Asn Ile His Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
 5 35 40 45
 Tyr Asn Val Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Ser Pro Trp
 10 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
 100 105

<210> 5
 <211> 357
 <212> DNA
 15 <213> Mus musculus

<400> 5
 caggctccagc tgcagcagtc tggggctgaa ctggcaagac ctggggcctc agtgaagatg 60
 tcctgcaagg ctcttggtta cacctttact aggtacacga tgcactgggt aaaacagagg 120
 20 cctggacagg gtctggaatg gattggatac attaatccta gccgtgggta tactaattac 180
 aatcagaagt tcaaggacaa ggccacattg actacagaca aatcctccag cacagcctac 240
 atgcaactga gcagcctgac atctgaggac tctgcagtct attactgtgc aagatattat 300
 gatgatcatt actgccttga ctactggggc caaggcacca ctctcacagt ctccctca 357

<210> 6
 <211> 119
 25 <212> PRT
 <213> Mus musculus

<400> 6
 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
 1 5 10 15
 30 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
 20 25 30
 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60
 35 Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
 100 105 110
 40 Thr Thr Leu Thr Val Ser Ser
 115

<210> 7
 <211> 321
 <212> DNA
 45 <213> Mus musculus

<400> 7
 caaattgttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gaaggctacc 60
 atgacctgca gtgccagctc aagtgttaagt tacatgaact ggtaccagca gaagtcaggc 120
 acctccccc aaagatggat ttatgacaca tccaaactgg ctcttgagat ccctgctcac 180
 50 ttcaggggca gtgggtcttg gacctttac tctctcaca tcagcggcat ggaggctgaa 240
 gatgctgcca ctattactg ccagcagtg agtagtaacc cattcacgtt cggctcgggg 300
 acaagatttg aaataaacg g 321

<210> 8
 <211> 107
 55 <212> PRT
 <213> Mus musculus

<400> 8
 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
 20 25 30
 Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
 35 40 45
 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser
 50 55 60
 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu
 65 70 75 80
 Asp Ala Ala Thr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr
 85 90 95
 Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg
 100 105

<210> 9
 <211> 1982
 <212> DNA
 <213> Artificial Sequence
 <223> Polynucleotide sequence coding bispecific antibody

<400> 9
 aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc 60
 gccccattga cgcaaatggg cggtaggcgt gtacgggtgg aggtctatat aagcagagct 120
 ctctggctaa ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat 180
 agggagaccc aagctggcta gccaccatgg agacagacac actcctgcta tgggtactgc 240
 tgctctgggt tccagggttcc actggtgacg cggcccagcc ggccaggcgc gccgtacgaa 300
 gcttacaggt ccagctgcag gagtcaggac ctggcctggg gaaaccttct cagtctctgt 360
 ccctcacctg cactgtcact ggccactcaa tcaccagtga ttatgcctgg aactggatcc 420
 ggcagtttcc aggagacaaa ctggagtggg tgggctacat aagctacagt gggtactact 480
 cctacaaccc atctctgaaa agtcgagtcct ctatcactcg agacacatcc aagaaccagt 540
 tcttcttgca gttgaattct gtgactactg aggacacagc cacatacttc tgtgcaagag 600
 accttgatta cggcccctgg ttgtcttact ggggccaagg gaccacggct accgtctcct 660
 caggttgagg cgggttcacaa attgtttctc cccagtcctc agcaatcatg tctgcatctc 720
 caggggagaa ggtcaccatg acctgcagtg ccagctcaag tgtaagttac atgaactggt 780
 accagcagaa gtcaggcacc tcccccaaaa gatggattta tgacacatcc aaactggcct 840
 ctggagtccc tgcctcattc aggggcagtg ggtctgggac ctcttactct ctcaaatca 900
 gcggcatgga ggctgaagat gctgccactt attactgcc a gcagtggagt agtaaccat 960
 tcacgttcgg ctccgggaca aagttggaag taaaccgggg tggaggcggg tcaggcggag 1020
 gtggctctgg cgggtggcggg tcgcagggtcc agctgcagca gtctggggct gaactggcaa 1080
 gacctggggc ctcaagtgaag atgtcctgca aggtctctgg ctacaccttt actaggtaca 1140
 cgatgcactg ggtaaaacag aggcctggac agggctctgga atggattgga tacattaatc 1200
 ctagccgtgg ttataactaat tacaatcaga agttcaagga caaggccaca ttgactacag 1260
 acaaatctc cagcacagcc tacatgcaac tgagcagcct gacatctgag gactctgcag 1320
 tctattactg tgcaagatat tatgatgatc attactgcct tgactactgg ggccaaggca 1380
 ccactctcac agtctcctca ggtggaggcg gttcagacat ccagatgacc cagtctccag 1440
 cctccctatc tgcattctgt ggagaaactg tcacctcac atgtcgagca agtgagaata 1500
 ttcacaatta tttagcatgg tatcagcaga aacagggaaa atctcctcag ctctggtct 1560
 ataattgtaa aaccttagca gatggtgtgc catcaagggt cagtggcagt ggatcaggaa 1620
 cacaatattc tctcaagatc aacagcctgc agcctgaaga ttttgggagt tattactgtc 1680
 aacatttttg gagtagtccg tggacgttcg gtggaggcac caagctggaa atcaaacggg 1740
 cggccgctcg aggaggggcc gaacaaaaac tcattctcaga agaggatctg aatagcgcg 1800
 tcgaccatca tcatcatcat cattgagttt aaaccgcgtg atcagcctcg actgtgcctt 1860
 ctagttgccg gccatctgtt gtttgccctt ccccggtgct ttccttgacc ctggaagggt 1920
 ccactccac tgtcctttcc taataaaatg aggaaattgc atcgattgt ctgagtaggt 1980
 gt
 1982

<210> 10
 <211> 1982
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (207)..(1823)
 <223> Polynucleotide and polypeptide sequence coding bispecific antibody

<400> 10																	
		aatgggagtt	tgttttggca	ccaaaatcaa	cgggactttc	caaaatgtcg	taacaactcc		60								
		gccccattga	cgcaaatggg	cggtaggcgt	gtacgggtggg	aggtctatat	aagcagagct		120								
		ctctggctaa	ctagagaacc	cactgcttac	tggttatcg	aaattaatac	gactcactat		180								
5		agggagaccc	aagctggcta	gccacc atg	gag aca gac	aca ctc ctg	cta tgg		233								
				Met	Glu Thr Asp	Thr Leu Leu	Trp										
				1		5											
		gta ctg ctg	ctc tgg gtt	cca ggt tcc	act ggt gac	gcg gcc cag	ccg		281								
		Val Leu Leu	Leu Trp Val	Pro Gly Ser	Thr Gly Asp	Ala Ala Gln	Pro										
		10	15	20	25												
10		gcc agg cgc	gcc gta cga	agc tta cag	gtc cag ctg	cag gag tca	gga		329								
		Ala Arg Arg	Ala Val Arg	Ser Leu Gln	Val Gln Leu	Gln Glu Ser	Gly										
			30	35	40												
		cct ggc ctg	gtg aaa cct	tct cag tct	ctg tcc ctc	acc tgc act	gtc		377								
		Pro Gly Leu	Val Lys Pro	Ser Gln Ser	Leu Ser Leu	Thr Cys Thr	Val										
			45	50	55												
15		act ggc cac	tca atc acc	agt gat tat	gcc tgg aac	tgg atc cgg	cag		425								
		Thr Gly His	Ser Ile Thr	Ser Asp Tyr	Ala Trp Asn	Trp Ile Arg	Gln										
			60	65	70												
		ttt cca gga	gac aaa ctg	gag tgg atg	ggc tac ata	agc tac agt	ggt		473								
		Phe Pro Gly	Asp Lys Leu	Glu Trp Met	Gly Tyr Ile	Ser Tyr Ser	Gly										
			75	80	85												
20		tac act acc	tac aac cca	tct ctg aaa	agt cga gtc	tct atc act	cga		521								
		Tyr Thr Thr	Tyr Asn Pro	Ser Leu Lys	Ser Arg Val	Ser Ile Thr	Arg										
			90	95	100												
		gac aca tcc	aag aac cag	ttc ttc ctg	cag ttg aat	tct gtg act	act		569								
		Asp Thr Ser	Lys Asn Gln	Phe Phe Leu	Gln Leu Asn	Ser Val Thr	Thr										
			110	115	120												
25		gag gac aca	gcc aca tac	ttc tgt gca	aga gac ctt	gat tac ggc	ccc		617								
		Glu Asp Thr	Ala Thr Tyr	Phe Cys Ala	Arg Asp Leu	Asp Tyr Gly	Pro										
			125	130	135												
		tgg ttt gct	tac tgg ggc	caa ggg acc	acg gtc acc	gtc tcc tca	ggt		665								
		Trp Phe Ala	Tyr Trp Gly	Gln Gly Thr	Thr Val Thr	Val Ser Ser	Gly										
			140	145	150												
30		gga ggc ggt	tca caa att	ggt ctc acc	cag tct cca	gca atc atg	tct		713								
		Gly Gly Gly	Ser Gln Ile	Val Leu Thr	Gln Ser Pro	Ala Ile Met	Ser										
			155	160	165												
		gca tct cca	ggg gag aag	gtc acc atg	acc tgc agt	gcc agc tca	agt		761								
		Ala Ser Pro	Gly Glu Lys	Val Thr Met	Thr Cys Ser	Ala Ser Ser	Ser										
			170	175	180												
35		gta agt tac	atg aac tgg	tac cag cag	aag tca ggc	acc tcc ccc	aaa		809								
		Val Ser Tyr	Met Asn Trp	Tyr Gln Gln	Lys Ser Gly	Thr Ser Pro	Lys										
			190	195	200												
		aga tgg att	tat gac aca	tcc aaa ctg	gct tct gga	gtc cct gct	cac		857								
		Arg Trp Ile	Tyr Asp Thr	Ser Lys Leu	Ala Ser Gly	Val Pro Ala	His										
			205	210	215												
40		ttc agg ggc	agt ggg tct	ggg acc tct	tac tct ctc	aca atc agc	ggc		905								
		Phe Arg Gly	Ser Gly Ser	Gly Thr Ser	Tyr Ser Leu	Thr Ile Ser	Gly										
			220	225	230												
		atg gag gct	gaa gat gct	gcc act tat	tac tgc cag	cag tgg agt	agt		953								
		Met Glu Ala	Glu Asp Ala	Ala Thr Tyr	Tyr Cys Gln	Gln Trp Ser	Ser										
			235	240	245												
45		aac cca ttc	acg ttc ggc	tcg ggg aca	aag ttg gaa	ata aac cgg	ggt		1001								
		Asn Pro Phe	Thr Phe Gly	Ser Gly Thr	Lys Leu Glu	Ile Asn Arg	Gly										
			250	255	260												
		gga ggc ggt	tca ggc gga	ggt ggc tct	ggc ggt ggc	gga tgc cag	gtc		1049								
		Gly Gly Gly	Ser Gly Gly	Gly Gly Ser	Gly Gly Gly	Gly Ser Gln	Val										
			270	275	280												
50		cag ctg cag	cag tct ggg	gct gaa ctg	gca aga cct	ggg gcc tca	gtg		1097								
		Gln Leu Gln	Gln Ser Gly	Ala Glu Leu	Ala Arg Pro	Gly Ala Ser	Val										
			285	290	295												
		aag atg tcc	tgc aag gct	tct ggc tac	acc ttt act	agg tac acg	atg		1145								
		Lys Met Ser	Cys Lys Ala	Ser Gly Tyr	Thr Phe Thr	Arg Tyr Thr	Met										
			300	305	310												
55		cac tgg gta	aaa cag agg	cct gga cag	ggt ctg gaa	tgg att gga	tac		1193								
		His Trp Val	Lys Gln Arg	Pro Gly Gln	Gly Leu Glu	Trp Ile Gly	Tyr										
			315	320	325												

	att aat cct agc cgt ggt tat act aat tac aat cag aag ttc aag gac	1241
	Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp	
	330 335 340 345	
5	aag gcc aca ttg act aca gac aaa tcc tcc agc aca gcc tac atg caa	1289
	Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln	
	350 355 360	
	ctg agc agc ctg aca tct gag gac tct gca gtc tat tac tgt gca aga	1337
	Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg	
	365 370 375	
10	tat tat gat gat cat tac tgc ctt gac tac tgg ggc caa ggc acc act	1385
	Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr	
	380 385 390	
	ctc aca gtc tcc tca ggt gga ggc ggt tca gac atc cag atg acc cag	1433
	Leu Thr Val Ser Ser Gly Gly Gly Ser Asp Ile Gln Met Thr Gln	
	395 400 405	
15	tct cca gcc tcc cta tct gca tct gtg gga gaa act gtc acc ctc aca	1481
	Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Leu Thr	
	410 415 420 425	
	tgt cga gca agt gag aat att cac aat tat tta gca tgg tat cag cag	1529
	Cys Arg Ala Ser Glu Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln	
	430 435 440	
20	aaa cag gga aaa tct cct cag ctc ctg gtc tat aat gta aaa acc tta	1577
	Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Val Lys Thr Leu	
	445 450 455	
	gca gat ggt gtg cca tca agg ttc agt ggc agt gga tca gga aca caa	1625
	Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln	
	460 465 470	
25	tat tct ctc aag atc aac agc ctg cag cct gaa gat ttt ggg agt tat	1673
	Tyr Ser Leu Lys Ile Asn Ser Glu Leu Gln Pro Glu Asp Phe Gly Ser Tyr	
	475 480 485	
	tac tgt caa cat ttt tgg agt agt ccg tgg acg ttc ggt gga ggc acc	1721
	Tyr Cys Gln His Phe Trp Ser Ser Pro Trp Thr Phe Gly Gly Gly Thr	
	490 495 500 505	
30	aag ctg gaa atc aaa cgg gcg gcc gct cga gga ggg ccc gaa caa aaa	1769
	Lys Leu Glu Ile Lys Arg Ala Ala Ala Arg Gly Gly Pro Glu Gln Lys	
	510 515 520	
	ctc atc tca gaa gag gat ctg aat agc gcc gtc gac cat cat cat cat	1817
	Leu Ile Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His His His His	
	525 530 535	
	cat cat tgagtttaaa cccgctgac agcctcgact gtgccttcta gttgccagcc	1873
	His His	
35	atctgttgtt tgccccctccc ccgtgccttc cttgaccctg gaaggtgccca ctcccactgt	1933
	cctttcctaa taaaatgagg aaatgcatc gcattgtctg agtaggtgt	1982
	<210> 11	
	<211> 539	
	<212> PRT	
40	<213> Artificial Sequence	
	<223> Polypeptide sequence coding bispecific antidody	
	<400> 11	
	Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro	
	1 5 10 15	
45	Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Arg Arg Ala Val Arg Ser	
	20 25 30	
	Leu Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser	
	35 40 45	
	Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly His Ser Ile Thr Ser	
	50 55 60	
50	Asp Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asp Lys Leu Glu	
	65 70 75 80	
	Trp Met Gly Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser	
	85 90 95	
	Leu Lys Ser Arg Val Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe	
	100 105 110	
55	Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe	
	115 120 125	
	Cys Ala Arg Asp Leu Asp Tyr Gly Pro Trp Phe Ala Tyr Trp Gly Gln	

130 135 140
 Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Gln Ile Val
 145 150 155 160
 Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val
 165 170 175
 5 Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr
 180 185 190
 Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser
 195 200 205
 Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser Gly Ser Gly
 210 215 220
 10 Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu Asp Ala Ala
 225 230 235 240
 Thr Tyr Tyr Cys Gln Trp Ser Ser Asn Pro Phe Thr Phe Gly Ser
 245 250 255
 Gly Thr Lys Leu Glu Ile Asn Arg Gly Gly Gly Gly Ser Gly Gly Gly
 260 265 270
 15 Gly Ser Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala
 275 280 285
 Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser
 290 295 300
 Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro
 305 310 315 320
 20 Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr
 325 330 335
 Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp
 340 345 350
 Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu
 355 360 365
 25 Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys
 370 375 380
 Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly
 385 390 395 400
 Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala
 405 410 415
 30 Ser Val Gly Glu Thr Val Thr Leu Thr Cys Arg Ala Ser Glu Asn Ile
 420 425 430
 His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln
 435 440 445
 Leu Leu Val Tyr Asn Val Lys Thr Leu Ala Asp Gly Val Pro Ser Arg
 450 455 460
 35 Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser
 465 470 475 480
 Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser
 485 490 495
 Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala
 500 505 510
 40 Ala Ala Arg Gly Gly Pro Glu Gln Lys Leu Ile Ser Glu Asp Leu
 515 520 525
 Asn Ser Ala Val Asp His His His His His His
 530 535

<210> 12
 <211> 1617
 <212> DNA
 <213> Artificial sequence
 <223> Polynucleotide sequence coding bispecific antibody

<400> 12
 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggg 60
 gacgcggccc agccggccag gcgcgccgta cgaagcttac aggtccagct gcaggagtca 120
 ggacctggcc tgggtgaaacc ttctcagctct ctgtccctca cctgcactgt cactggccac 180
 tcaatcacca gtgattatgc ctggaactgg atccggcagt ttccaggaga caaactggag 240
 tggatgggct acataagcta cagtggttac actacctaca acccatctct gaaaagtcga 300
 gtctctatca ctcgagacac atccaagaac cagttcttcc tgcagttgaa ttctgtgact 360
 actgaggaca cagccacata cttctgtgca agagacctg attacggccc ctggtttgct 420
 tactggggcc aagggaccac ggtcaccgtc tcctcaggtg gaggcgggtc acaaattggt 480
 ctcaccagct ctccagcaat catgtctgca tctccagggg agaaggtcac catgacctgc 540

	agtgccagct	caagtgtaag	ttacatgaac	tggtaccagc	agaagtcagg	cacctcccc	600
	aaaagatgga	ttatgacac	atccaaactg	gcttctggag	tccctgctca	cttcaggggc	660
	agtgggtctg	ggacctctta	ctctctcaca	atcagcggca	tggaggctga	agatgctgcc	720
	acttattact	gccagcagtg	gagtagtaac	ccattcacgt	tcggctcggg	gacaaagtgtg	780
5	gaaataaacc	gggtgagg	cggttcaggc	ggagggtggt	ctggcgggtg	cgatcgag	840
	gtccagctgc	agcagtctgg	ggctgaactg	gcaagacctg	gggcctcagt	gaagatgtcc	900
	tgcaaggctt	ctggctacac	ctttactagg	tacacgatgc	actgggtaaa	acagaggcct	960
	ggacagggtc	tggatggat	tggatacatt	aatcctagcc	gtggttatac	taattacaat	1020
	cagaagttca	aggacaaggc	cacattgact	acagacaaat	cctccagcac	agcctacatg	1080
	caactgagca	gcctgacatc	tgaggactct	gcagtctatt	actgtgcaag	atattatgat	1140
10	gatcattact	gccttgacta	ctggggccaa	ggcaccactc	tcacagtctc	ctcagggtgga	1200
	ggcgggttcag	acatccagat	gaccagctct	ccagcctccc	tatctgcatc	tgtgggagaa	1260
	actgtcacc	tcacatgtcg	agcaagtgg	aatattcaca	attatttagc	atggtatcag	1320
	cagaaacagg	gaaaatctcc	tcagctcctg	gtctataatg	taaaaacctt	agcagatggt	1380
	gtgccatcaa	ggttcagtgg	cagtggatca	ggaacacaat	attctctcaa	gatcaacagc	1440
	ctgcagcctg	aagattttgg	gagttattac	tgtaaacatt	tttggagtag	tccgtggagc	1500
15	ttcgggtggag	gcaccaagct	ggaaatcaaa	cgggcggccg	ctcaggagg	gcccgaacaa	1560
	aaactcatct	cagaagagga	tctgaatagc	gccgtcgacc	atcatcatca	tcatcat	1617

<210> 13

<211> 1434

<212> DNA

<213> Artificial Sequence

<223> Polynucleotide sequence coding bispecific antibody

<400> 13

	cagggtccagc	tgcaggagtc	aggacctggc	ctgggtgaaac	cttctcagtc	tctgtccctc	60
	acctgcactg	tcactggcca	ctcaatcacc	agtgattatg	cctggaactg	gatccggcag	120
	tttccaggag	acaaaactgga	gtggatgggc	tacataagct	acagtgggtta	actacacctac	180
25	aacctatctc	tgaaaagtcg	agtctctatc	actcgagaca	catccaagaa	ccagttcttc	240
	ctgcagttga	attctgtgac	tactgaggac	acagccacat	acttctgtgc	aagagacctt	300
	gattacggcc	cctggtttgc	ttactggggc	caagggacca	cggtcaccgt	ctcctcaggt	360
	ggaggcggtt	cacaaattgt	tctcaccag	tctccagcaa	tcatgtctgc	atctccaggg	420
	gagaagggtca	ccatgacctg	cagtgccagc	tcaagtgtaa	gttacctgaa	ctggtaccag	480
	cagaagtcag	gcacctcccc	caaaagatgg	atttatgaca	catccaaact	ggcttctgga	540
30	gtccctgtct	acttcagggg	cagtgggtct	gggacctctt	actctctcac	aatcagcggc	600
	atggaggctg	aagatgctgc	cacttattac	tgccagcagt	ggagtagtaa	cccatcacg	660
	ttcggctcgg	ggacaaagtt	ggaaataaac	cgggggtggag	gcggttcagg	cggagggtggc	720
	tctggcggtg	gcggatcgca	ggtccagctg	cagcagctctg	gggctgaact	ggcaagacct	780
	ggggcctcag	tgaagatgtc	ctgcaaggct	tctggctaca	ctttactag	gtacacgatg	840
	cactgggttaa	aacagaggcc	tggacagggt	ctggaaatgga	ttggatacat	taatcttagc	900
35	cgtggttata	ctaattacaa	tcagaagttc	aaggacaagg	ccacattgac	tacagacaaa	960
	tcctccagca	cagcctacat	gcaactgagc	agcctgacat	ctgaggactc	tgcagtctat	1020
	tactgtgcaa	gatattatga	tgatcattac	tgcttgact	actggggcca	aggcaccact	1080
	ctcacagtct	cctcagggtg	aggcggttca	gacatccaga	tgaccagtc	tccagcctcc	1140
	ctatctgcat	ctgtgggaga	aactgtcacc	ctcacatgtc	gagcaagtga	gaatattcac	1200
	aattatttag	catggtatca	gcagaaacag	ggaaaatctc	ctcagctcct	ggtctataat	1260
40	gtaaaaacct	tagcagatgg	tgtgccatca	aggttcagtg	gcagtggatc	aggaacacaa	1320
	tattctctca	agatcaacag	cctgcagcct	gaagattttg	ggagttatta	ctgtcaacat	1380
	ttttggagta	gtccgtggac	gttcgggtgga	ggcaccaagc	tggaaatcaa	acgg	1434

<210> 14

<211> 34

<212> DNA

<213> Artificial Sequence

<223> PCR primer oligonucleotide

<400> 14

ttttttaagc ttacaggtcc agctgcagga gtca 34

<210> 15

<211> 34

<212> DNA

<213> Artificial Sequence

<223> PCR primer oligonucleotide

<400> 15

ttttttgcgg ccgcccgggtt tatttccaac ttg 34

<210> 16
 <211> 34
 <212> DNA
 <213> Artificial Sequence
 <223> PCR primer oligonucleotide
 5
 <400> 16
 ttttttaagc ttacaggtcc agctgcagca gtct 34

<210> 17
 <211> 34
 <212> DNA
 <213> Artificial Sequence
 <223> PCR primer oligonucleotide
 10
 <400> 17
 ttttttgagg ccgcccgttt gatttccagc ttgg 34

<210> 18
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <223> PCR primer oligonucleotide
 20
 <400> 18
 atgaactggt accagcagaa g
 21

<210> 19
 <211> 65
 <212> DNA
 <213> Artificial Sequence
 <223> Linker oligonucleotide
 25
 <400> 19
 agggaccacg gtcaccgtct cctcaggtgg aggcggttca caaattgttc tcacccagtc 60
 tccag
 65

<210> 20
 <211> 65
 <212> DNA
 <213> Artificial Sequence
 <223> Linker oligonucleotide
 35
 <400> 20
 ctggagactg ggtgagaaca atttgtgaac cgctccacc tgaggagacg gtgaccgtgg 60
 tccct
 65

<210> 21
 <211> 65
 <212> DNA
 <213> Artificial Sequence
 <223> Linker oligonucleotide
 45
 <400> 21
 aggcaccact ctcacagtct cctcaggtgg aggcggttca gacatccaga tgacccagtc 60
 tccag
 65

<210> 22
 <211> 65
 <212> DNA
 <213> Artificial Sequence
 <223> Linker oligonucleotide
 55

<400> 22
 ctggagactg ggtcatcttg atgtctgaac cgcctccacc tgaggagact gtgagagtgg 60
 tgcct 65

5 <210> 23
 <211> 95
 <212> DNA
 <213> Artificial Sequence
 <223> Linker oligonucleotide

10 <400> 23
 ggggacaaag ttggaaataa accggggttg aggcggttca ggcggaggtg gctctggcgg 60
 tggcggatcg caggtccagc tgcagcagtc tgggg 95

15 <210> 24
 <211> 95
 <212> DNA
 <213> Artificial Sequence
 <223> Linker oligonucleotide

20 <400> 24
 ccccagactg ctgcagctgg acctgcgac cgccaccgcc agagccacct ccgcctgaac 60
 cgcctccacc ccggtttatt tccaactttg tcccc 95

25 <210> 25
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 <223> Linker polypeptide

<400> 25
 Gly Gly Gly Gly Ser
 1 5

30 <210> 26
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <223> Linker polypeptide

35 <400> 26
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

40 Claims

1. A substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells, and a linker.
- 45 2. The substance specific to human PD-1 according to claim 1, wherein the part that recognizes human PD-1 is an antibody against human PD-1 or a partial fragment thereof.
3. The substance specific to human PD-1 according to claim 1, wherein the part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells is an antibody against the membrane protein or a partial fragment thereof.
- 50 4. The substance specific to human PD-1 according to claim 1, comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against the membrane protein on cell membrane of human PD-1-expressing cells or a partial fragment thereof, and a linker.
- 55 5. The substance specific to human PD-1 according to any one of claims 1, 3 and 4, wherein the membrane protein is human T cell receptor complex or human B cell receptor complex.

6. The substance specific to human PD-1 according to claim 1 or 4, wherein the linker is a peptide.
7. A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human T cell receptor complex or a partial fragment thereof, and a linker.
8. A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human B cell receptor complex or a partial fragment thereof, and a linker.
9. The bispecific antibody according to claim 7 or 8, wherein the linker is a peptide.
10. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
11. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:4, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
12. A polypeptide complex comprising the polypeptides according to claims 10 and 11.
13. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added.
14. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, which is the bispecific antibody according to any one of claims 7 to 9.
15. A polynucleotide encoding the polypeptide according to any one of claims 10, 11, 13 and 14, a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
16. A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9, a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
17. A duplication or expression vector comprising the polynucleotide according to claim 15 or 16.
18. A host cell transformed by the duplication or expression vector according to claim 17.
19. A manufacturing method of the substance according to any one of claims 1 to 6, comprising culturing the host cell according to claim 18 under conditions to express the substance.
20. A manufacturing method of the bispecific antibody according to any one of claims 7 to 9, comprising culturing the host cell according to claim 18 under conditions to express the bispecific antibody.
21. A manufacturing method of the polypeptide according to any one of claims 10 to 14, comprising culturing the host cell according to claim 18 under conditions to express the polypeptide.
22. A therapeutic and/or preventive pharmaceutical composition for human PD-1 related-diseases, comprising an effective amount of the substance according to any one of claims 1 to 6, the bispecific antibody according to any one of claims 7 to 9, the polypeptide complex according to claim 12, or the polypeptide according to claim 13 or 14.
23. The therapeutic and/or preventive pharmaceutical composition according to claim 22, wherein the human PD-1 related-diseases are diseases selected from neurodegenerative disease, autoimmune disease, collagenosis, organ transplantation rejection, tumour, and infectious disease.

- 4 24. The therapeutic and/or preventive pharmaceutical composition according to claim 22, wherein the neurodegenerative diseases are diseases selected from geropsychosis, Alzheimer disease, Down syndrome, Parkinson's disease, Creutzfeldt-jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt-Jakob disease.
- 5
25. The therapeutic and/or preventive pharmaceutical composition according to claim 22, wherein the autoimmune diseases are diseases selected from glomerular nephritis, arthritis, dilated cardiomyopathy-like disease, ulcerous colitis, Sjogren syndrome, Crohn disease, systemic erythematodes, chronic rheumatoid arthritis, multiple sclerosis, psoriasis, allergic contact dermatitis, polymyositis, pachyderma, periarteritis nodosa, rheumatic fever, vitiligo vulgaris, insulin dependent diabetes mellitus, Behcet disease, Hashimoto disease, Addison disease, dermatomyositis, myasthenia gravis, Reiter syndrome, Graves' disease, anaemia perniciousa, Goodpasture syndrome, sterility disease, chronic active hepatitis, pemphigus, autoimmune thrombopenic purpura, and autoimmune hemolytic anemia.
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55

FIG. 1




FIG. 2





FIG. 3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000549

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ C12N15/13, C07K16/46, C12P21/08, C12N5/10, A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ C12N15/00-15/90, C07K14/00-16/46, C12P1/00-41/00,
C12N1/00-9/99, A61K31/00-48/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

SwissProt/PIR/GeneSeq, GenBank/EMBL/DDBJ/GeneSeq, WPI (STN),
BIOSIS (STN), MEDLINE (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Wayne W. Hancock3 et al., "Programmed Death-1 Targeting Can Promote Allograft Survival.", The Journal of Immunology, Vol.169, (2002), pages 6546 to 6553	1-25
Y	Honjo T. et al., "PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.", Eur.J.Immunol., Vol.32, No.3, (2002), pages 634 to 643	1-25
Y	Margitta Alt et al., "Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin 1 Fc or CH3 region.", FEBS Letters, Vol.454, Issues 1-2, (1999), pages 90 to 94	1-25

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
02 June, 2004 (02.06.04)Date of mailing of the international search report
22 June, 2004 (22.06.04)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000549

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Peter J. et al., "High avidity scFv multimers; diabodies and triabodies.", Journal of Immunological Methods, Vol.231, (1999), pages 177 to 189	1-25
Y	WO 2001/064249 A1 (Chugai Pharmaceutical Co., Ltd.), 07 September, 2001 (07.09.01), & JP 2001-563146 A	1-25

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000549

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material

☒ a sequence listing

☐ table(s) related to the sequence listing

b. format of material

☐ in written format

☒ in computer readable form

c. time of filing/furnishing

☐ contained in the international application as filed

☒ filed together with the international application in computer readable form

☐ furnished subsequently to this Authority for the purposes of search

2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: